|OX40 Ligand||CHEK-ATP054||HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line|
|OX40||CHEK-ATP053||HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line|
|4-1BB Ligand||CHEK-ATP039||HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line|
|4-1BB||CHEK-ATP038||HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line|
|4-1BB||CHEK-ATF073||Human 4-1BB (Luc) HEK293 Reporter Cell|
|CD40||CHEK-ATF097||Human CD40 (Luc) HEK293 Reporter Cell|
The purity of Human OX40 Ligand, His Tag (active trimer) (Cat. No. OXL-H52Q8) is more than 95% in HP-SEC, and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.
The purity of Human / Cynomolgus / Rhesus macaque CD28, His Tag, active dimer (Cat. No. CD8-H52Hc) is more than 90% and the molecular weight of this protein is around 58-75 kDa verified by SEC-MALS.
Immobilized Human 4-1BB, His Tag (Cat. No. 41B-H52Hc) at 1 μg/mL (100 μL/well) can bind Utomilumab with a linear range of 0.1-4 ng/mL (Routinely tested).
Human UreluMab captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human 4-1BB, His Tag (Cat. No. 41B-H52Hc) with an affinity constant of 3.59 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
FACS assay shows that Monoclonal UreluMab antibody, Human IgG4 can bind to HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line (CHEK-ATP038). HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Flow Cytometry assay shows that Human 4-1BB Protein, Mouse IgG2a Fc Tag (Cat. No. 41B-H5256) can bind to 293T cells overexpressing Human 4-1BBL.The concentration of 4-1BB used is 0.03 μg/mL (Routinely tested).
Human CD40 Ligand, His,Flag Tag (Cat. No. CDL-H52Db) stimulates secretion of IL-6 by human B cells. The ED50 for this effect is 18.76-19.45 ng/mL in the presence of 5 ng/mL of Recombinant Human IL 4 (Routinely tested).
Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).
1. Choi Y, Shi Y, Haymaker CL, Naing A, Ciliberto G, Hajjar J. T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2):e000966. doi: 10.1136/jitc-2020-000966.
2. Elgueta R, Benson MJ, de Vries VC, et al.. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–72.